Jacobs Levy Equity Management’s Rubius Therapeutics RUBY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-544,238
Closed -$236K – 1075
2022
Q3
$236K Buy
+544,238
New +$408K ﹤0.01% 920
2022
Q1
– Sell
-12,771
Closed -$124K – 1115
2021
Q4
$124K Sell
12,771
-13,210
-51% -$183K ﹤0.01% 953
2021
Q3
$465K Hold
25,981
– – ﹤0.01% 868
2021
Q2
$634K Sell
25,981
-12,565
-33% -$314K ﹤0.01% 824
2021
Q1
$1.02M Sell
38,546
-356,363
-90% -$5.21M 0.01% 733
2020
Q4
$3M Sell
394,909
-7,646
-2% -$45.4K 0.03% 496
2020
Q3
$2.02M Buy
402,555
+30,690
+8% +$163K 0.02% 518
2020
Q2
$2.22M Buy
+371,865
New +$2.2M 0.02% 515

Other funds holding RUBY

Jacobs Levy Equity Management's RUBY Position: Q4 2022 in Review

Jacobs Levy Equity Management sold out of Rubius Therapeutics (RUBY) in Q4 2022, closing a stake of 544,238 shares — an estimated $236K sold.

Jacobs Levy Equity Management first reported a position in RUBY in Q2 2020 and held it in 8 quarters. The position peaked at $3M in Q4 2020. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Jacobs Levy Equity Management reported no remaining Rubius Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 544,238 Rubius Therapeutics shares in Q4 2022, an estimated $236K.
  • Jacobs Levy Equity Management first reported a position in Rubius Therapeutics in Q2 2020 and held it in 8 quarters.
  • Jacobs Levy Equity Management's Rubius Therapeutics position peaked at $3M in Q4 2020.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics as of Q4 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.